A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod
This study enrolls adults with Relapsing Multiple Sclerosis. The purpose of this study is to learn about changes in cognition that happen while being treated with the experimental medication RPC1063 (also known as ozanimod).
You will be in this study for about 40 months altogether. You will come for clinic visits about every 3 months. At different points during the study you will have physical and neurological examinations, have your blood taken, and have EKGs and MRIs done. You will also complete surveys and have some cognitive testing done. All of these things will be done yearly. You will also be given the investigational drug. Study takes place at UBMD Neurology locations in Buffalo, NY.
The primary objective of the study is to describe the change from baseline in cognitive processing speed, measured by the Symbol Digit Modalities Test (SDMT), in subjects treated with ozanimod hydrochloride (HCl) 1 mg at 3 years.
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
- Adults ages 18-65.
- Have at least 5 years since time of RMS diagnosis.
- Have no clinically relevant cardiovascular conditions.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the
contact information above or email email@example.com and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality
assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided
in the aforementioned ways, please contact firstname.lastname@example.org.